Inclusion Criteria:  Confirmed clinical diagnosis of cystic fibrosis (CF). Arm 1 participants with genotype homozygous for the F508del CF transmembrane conductance regulator (CFTR) mutation and not receiving elexacaftor/tezacaftor/ivacaftor (ETI) treatment . Arm 2 and 3 participants with genotype heterozygous for the F508del CFTR mutation and a minimal function and not receiving ETI treatment. Arm 4 participants with genotype either homozygous or heterozygous for the F508del mutation. Participants must be receiving stable (ETI) treatment. Percent predicted forced expiratory volume in 1 second (ppFEV1) >= 40% and <=90% of predicted normal for age, gender and height at screening. For arms 1,2 and 3: sweat chloride (SwCl) >= 60 mmol/L at screening. For participants who participated in Study M19-530, it is acceptable to use a SwCl value that the central lab provided in Study M19-530 to establish eligibility. Weight >= 35 kg at screening and Day -28 for arm 1 or day 1 for arms 2 to 4.  Exclusion Criteria:  - Clinically significant laboratory values at screening that would pose undue risk for the participant or interfere with safety assessments (per the investigator).